论文部分内容阅读
利妥昔单抗(Rituximab,美罗华)是美国药品与食品管理局(FDA)批准用于肿瘤治疗的第一个单克隆抗体。它是一种人鼠嵌合型IgG1,相对分子量约144kDa,由鼠抗CD20单克隆抗体的可变区Fab和人IgG1抗体稳定区Fc片断嵌合而成,具有与天然鼠抗体相同的亲和力和人组织反应性。CD20是一个33-3
Rituximab (Rituximab, Rituximab) is the first monoclonal antibody approved by the U.S. Food and Drug Administration for cancer treatment. It is a human mouse chimeric IgG1 with a relative molecular weight of about 144 kDa. It is made of the chimeric Fab fragment of the variable region of the murine anti-CD20 monoclonal antibody and the Fc fragment of the human IgG1 antibody stable region and has the same affinity as the natural murine antibody and Human tissue reactivity. CD20 is a 33-3